Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.39B 2.96B 2.72B 2.54B 4.82B 323B 4.89B 32.71B 12.72B 159B 12.73B 12.46B 547B P/E 2026 *
-45.9x
P/E 2027 * -86.1x
Enterprise Value 3.27B 2.86B 2.63B 2.45B 4.65B 312B 4.72B 31.58B 12.28B 153B 12.29B 12.03B 528B EV / Sales 2026 *
11.4x
EV / Sales 2027 * 9.19x
Free-Float
98.07%
Yield 2026 *
-
Yield 2027 * -
1 day-5.27%
1 week+1.10%
Current month-1.21%
1 month+32.52%
3 months+43.08%
6 months+33.19%
Current year+30.48%
1 week 20.7
Extreme 20.705
22.8
1 month 15.9
Extreme 15.9
22.8
Current year 12
Extreme 12
22.8
1 year 9.96
Extreme 9.9551
22.8
3 years 2.28
Extreme 2.28
22.8
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2009-09-07
Chief Executive Officer 51 2009-09-07
Director of Finance/CFO 42 2024-04-07
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 2013-01-31
Director/Board Member 70 2013-11-30
Date Insider Type Main position Quantity % Market Cap.
06-28Fiscal year

Executive/Senior Manager

361,358 0.2258%
06-24Fiscal year

Director

156,252 0.0976%
06-24Sell

Executive/Senior Manager

-5,000 0.0031%
Change 5-day change 1-year change 3-year change Capi.($)
-5.27%+1.10%+79.58%+217.22% 3.39B
+0.95%-.--%+96.61%+12.37% 20.03B
-4.63%-5.64%+107.49%+129.05% 4.55B
+2.15%+5.68%-25.47%-39.18% 2.07B
+8.56%+1.41%+146.29%-39.30% 1.92B
-0.21%+1.28%+51.72%+243.82% 1.51B
-1.79%-2.89%+126.22%-51.45% 891M
+2.32%+6.54%-34.86%-16.56% 498M
-0.83%+8.52%-5.51% - 473M
-3.10%+0.95% - - 191M
Average -0.18%-0.76%+60.23%+57.00% 3.55B
Weighted average by Cap. -0.02%+0.43%+87.54%+49.59%

Financials

2026 *2027 *
Net sales 287M 251M 231M 215M 408M 27.35B 414M 2.77B 1.08B 13.44B 1.08B 1.05B 46.32B 352M 308M 283M 264M 500M 33.53B 508M 3.4B 1.32B 16.48B 1.32B 1.29B 56.79B
Net income -71.97M -62.92M -57.82M -53.89M -102M -6.85B -104M -694M -270M -3.37B -270M -264M -11.61B -38.02M -33.24M -30.55M -28.47M -54M -3.62B -54.82M -367M -143M -1.78B -143M -140M -6.13B
Net Debt -117M -102M -93.8M -87.43M -166M -11.12B -168M -1.13B -438M -5.46B -438M -429M -18.83B -157M -137M -126M -117M -222M -14.91B -226M -1.51B -587M -7.33B -588M -575M -25.25B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
26-07-02 US$21.19 -5.27% 3,393,935
26-07-01 US$22.37 +4.29% 3,284,993
26-06-30 US$21.45 +0.23% 3,421,386
26-06-29 US$21.40 +2.10% 3,524,441
26-06-26 US$20.96 +3.51% 6,474,446
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
21.19USD
Average target price
20.29USD
Spread / Average Target
-4.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock